Condition: Muscular Dystrophy, Facioscapulohumeral · Sponsor: Jeffrey Statland
The purpose of this study is to determine if Clenbuterol is a therapeutic option for FSHD by determining the safety and tolerability of the medication at three different dose levels.
This description comes directly from the study's public registry record.
Rebecca Clay · 9139459936 · rclay@kumc.edu
Always discuss trial participation with your own doctor first.
| University of Kansas Medical Center | Kansas City, Kansas, United States | Recruiting |
| University of Rochester Medical Center | Rochester, New York, United States | Recruiting |
| University of Washington | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06721299